Novartis stock before the bell after a 13.9 percent drop

Novartis stock closed at USD 137.70 on the Cboe on September 8, 2026, down 13.9 percent from the prior session. The move came after a sharp selloff in the U.S.-listed line tied to fresh clinical-trial disappointment.

September 8, 2026 in numbers

Novartis AG (ISIN CH0012005267) ended the session after Reuters reported that the company said its Phase III HARBOR study of del-desiran did not meet its primary endpoint, while Novartis reaffirmed its sales guidance through 2030. Reuters also said the setback followed another late-stage trial miss announced on the prior day. The shares closed below the prior U.S. session level by 13.9 percent, and MarketScreener showed a 5-day move of minus 13.91 percent into the close.

MarketScreener listed the last close at USD 137.74 with volume of 417,925 shares, while Reuters-linked market reports said the Swiss shares were down 10.9 percent on the home exchange on September 8, 2026. The U.S. close also sat well below the recent range shown on the quote page, keeping the move anchored to the same session and the same news flow.

Today before the bell

Novartis has an RBC rating update dated September 9, 2026 on MarketScreener, which adds a fresh analyst note to the session mix. The broader market starts the day after S&P 500, Dow Jones and Nasdaq declines reported for September 8, 2026, a backdrop that can still shape early trading in health care names.